Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1801342-60-8
Molecular formula
Not available
Molecular weight
Not available
Drug class
Programmed cell death protein 1 (PD-1) immune-checkpoint inhibitormonoclonal antibody
Mechanism of action
Binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1-mediated inhibition of antitumour T-cell activity and restoring immune recognition and killing of tumour cells.
Indications / reported uses
Treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in patients who are not candidates for curative surgery or radiation
Treatment of locally advanced or metastatic basal cell carcinoma (BCC) after hedgehog pathway inhibitor therapy or when such therapy is inappropriate
Treatment of selected advanced non-small-cell lung cancer (NSCLC) settings; combination and biomarker criteria depend on current product label and jurisdiction
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Cemiplimab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cemiplimab Permitted Daily Exposure (PDE) report (the Cemiplimab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cemiplimab Occupational Exposure Limit (OEL) report (the Cemiplimab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.